David Young
Pulmonary Disease · Lansing, MINPI 1548230329
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,350 of the $35,941 with a category attached, or 87.2%. Boehringer Ingelheim accounts for 90.6% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $15,065 and has fallen 99.6% since, to $54 in 2023. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $140.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$33K
- AstraZeneca$672
- GSK$624
- Grifols USA, LLC$603
- Mylan Specialty L.p.$206
- Insmed, Inc.$178
- plus $1K from 26 others
What the payments were for
- Speaking & faculty fees$31,35087%
- Travel & lodging$4321%
- Food & beverage$4,08511%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 70 | $32,551 |
| AstraZeneca(2 entities) | 35 | $672 |
| GSK | 35 | $624 |
| Grifols USA, LLC | 38 | $603 |
| Mylan Specialty L.p. | 11 | $206 |
| Insmed, Inc. | 3 | $178 |
| Sanofi | 8 | $155 |
| Regeneron Healthcare Solutions, Inc. | 5 | $109 |
| Jazz Pharmaceuticals Inc. | 6 | $108 |
| Genentech USA, Inc. | 7 | $106 |
| Actelion Pharmaceuticals US, Inc. | 4 | $71 |
| Merck | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| United Therapeutics Corporation | 3 | $51 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Resmed Corp | 2 | $46 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Electromed, Inc. | 2 | $27 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| Melinta Therapeutics, LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Advanced Respiratory, Inc | 1 | $19 |
| Circassia Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Harmony Biosciences LLC | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Covidien LP | 1 | $13 |
| Pulmonx Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$211
How this compares
$35,941 in reported general payments places this provider in the 90th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Lansing
- Jennifer ElyLansing$34K
- Michael MasnyjLansing$16K
- Corey ObrienLansing$15K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.